48
Participants
Start Date
October 13, 2016
Primary Completion Date
November 1, 2017
Study Completion Date
November 1, 2017
Creon36™
Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
Children's Hospital of Philadelphia, Philadelphia
Collaborators (1)
AbbVie
INDUSTRY
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Phoenix Indian Medical Center
UNKNOWN
Children's Hospital of Philadelphia
OTHER